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Objectives: The primary aim was to assess the psychometric properties (including internal 
consistency, construct validity, reproducibility, and factor structure) of the Central Sensitization 
Inventory (CSI), adapted and validated for a Brazilian population (CSI-BP). Additionally, we 
evaluated the relationship between the CSI-BP and the serum brain-derived neurotrophic factor 
(BDNF) and determined if the symptoms elicited by the CSI-BP discriminate between subjects 
who do/do not respond to the conditioned pain modulation (CPM) task, as assessed by change 
in numeric pain scale (0–10) score.
Patients and methods: A cross-sectional study was conducted in a pain clinic in a tertiary 
teaching hospital. A total of 222 adults with chronic musculoskeletal pain and 63 healthy control 
subjects completed the CSI-BP and the Brazilian Portuguese pain-catastrophizing scale (BP-
PCS). A team of experts translated the CSI according to the international guidelines. Test–retest, 
item analysis, convergent validity, and factor analysis were performed. Later, a random subsample 
(n=77) was used to correlate the CSI-BP adjusted index with change in numeric pain-scale score 
during the CPM task and a BDNF blood sample.
Results: The CSI-BP presented strong psychometric properties (test–retest reliability 0.91, 
Cronbach’s a=0.91). Confirmatory factor analysis yielded a four-factor structure, supporting the 
original English version. The CSI-BP adjusted index showed moderate positive correlation with 
the BP-PCS, and classified more than 80% of patients correctly vs healthy controls. Serum BDNF 
levels explained 27% of the variation in the CSI-BP adjusted index. Subjects with impairment 
in the descending modulatory system had higher CSI-BP adjusted index scores than subjects 
who responded normally to the CPM task: 49.35 (12.1) vs 39.5 (12.33), respectively (P<0.05).
Conclusion: The CSI-BP was found to be a psychometrically strong and reliable instrument, 
with primary evidence of validity. Higher scores on the CSI-BP were correlated positively with 
serum BDNF and with greater dysfunction of the descending pain-modulatory system.
Keywords: confirmatory factor analysis, cross-cultural adaptation, conditioned pain modulation, 
serum brain-derived neurotrophic factor, central sensitization, chronic pain
Introduction
Chronic pain is one of the most prominent causes of disability worldwide. A meta-anal-
ysis of population studies showed an estimated prevalence of widespread chronic pain 
of 14.2%.1 Another meta-analysis found a predominance of chronic musculoskeletal 
pain in elderly Brazilians of 14.1%–85.5%.2 It is often associated with other clinical 
symptoms, including fatigue, poor sleep, cognitive deficits, headaches, depression, 
and anxiety.3 These symptoms are frequently related to central  sensitization (CS), 
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 identified in many disorders. CS has overlapping symptoms in 
a spectrum of structural pathology, from those with persistent 
nociception, eg, osteoarthritis (OA), to those without physical 
tissue damage, such as fibromyalgia (FM) and myofascial 
pain syndrome (MPS).4 Yunus proposed the term “central 
sensitivity syndrome’’ (CSS) to categorize inorganic pain-
related disorders with overlapping symptom dimensions, 
with CS being the common etiology.5
CS and associated symptoms are a consequence of 
changes in the central nervous system (CNS) that amplify 
the response to nociceptive inputs and fail to suppress noise 
signals, rather than just reflecting the presence of informa-
tion in a set of sensory fibers.6,7 This syndrome comprises 
impaired functioning of neurons and circuits in nociceptive 
pathways, increased membrane excitability and synaptic 
efficacy, and reduced inhibition.8 Sensitized neurons of the 
spinal dorsal horn exhibit increased spontaneous activity, 
reduction in threshold for activation, and an enlargement of 
their receptive fields.8 Furthermore, CS-related changes have 
been found in the microglia, astrocytes, gap junctions, and 
gene transcription, contributing to the maintenance of the 
general state of excitation. Since the release of brain-derived 
neurotrophic factor (BDNF) is part of spinal microglial activa-
tion, it contributes to both induction and maintenance of CS.9 
These impairments in pain circuits lead to the hypersensitiv-
ity observed in many chronic pain conditions. However, few 
tools have been available to help clinicians to identify when a 
patient presents symptoms that may be related to CS or may 
indicate the presence of CSS. The CS inventory (CSI) is a 
self-report questionnaire of health symptoms designed as an 
easy-to-administer screener for patients who are at high risk 
of having CS or to assess CS-related symptoms. The use of 
the CSI has also been recommended as one component of an 
algorithm to help classify chronic pain patients10 and low-
back pain patients11 with CS and to help differentiate them 
from patients with primary neuropathic and nociceptive pain. 
Most recently, five CSI severity levels have been proposed to 
aid clinical interpretation and evaluation of treatment respon-
siveness.12 The CSI is currently available in English, Central 
American Spanish, and Dutch13 and is being translated and 
validated in other European and Asian languages.14–18
Considering that chronic pain is highly prevalent across 
cultures, the recognition that it is often related to CS neces-
sitates having a reliable instrument to assess CS-related 
symptoms and to analyze the relationship of its score with 
neuroplasticity biomarkers. The primary aim was to assess 
the psychometric properties (including internal consistency, 
construct validity, reproducibility, and factor structure) of 
the CSI adapted and validated for a Brazilian population 
(CSI-BP). Additionally, we evaluated the relationship of 
the CSI-BP with serum BDNF and determined the ability 
of CSI-BP symptoms to discriminate between subjects who 
do/do not respond to a conditioned pain modulation (CPM) 
task, as assessed by change in a numeric pain scale (0–10).
Our hypothesis was that the degree of symptoms indexed 
by total CSI-BP scores would identify the severity of CS, 
according to the physiopathology of pain condition, such as 
FM, MPS, chronic tension-type headache (CTTH), OA, and 
pain-free healthy control subjects. Also, we hypothesized that 
CSI-BP scores would be correlated positively with blood 
levels of BDNF and would discriminate between subjects 
who did/did not respond to a CPM task.
Patients and methods
The protocol was reviewed and approved by the ethics com-
mittee board of the Hospital de Clínicas de Porto Alegre 
(protocol 10-0555). All subjects gave their written informed 
consent before participation.
Phase I: translation, synthesis, and  
back-translation
The procedures for the translation and adaptation of the CSI 
to Brazilian Portuguese and assessment of the semantics 
and conceptual content of each item (content validity) were 
conducted through the Delphi method (see Supplementary 
material).
Phase II: pretesting CSI-BP in pilot version
Thirty medical school employees (15 women) who work with 
chronic pain patients volunteered to evaluate the meaning of 
the translated items and the layout of the “prefinal” version of 
the CSI-BP. Also, 20 females with FM who had volunteered 
to evaluate the meaning of the translated CSI-BP questions 
were included and they completed the CSI-BP twice,  and 
the interval for test–retest reliability of the CSI-BP was 15 
days. The assessment regarding the comprehension of the 
items and all feedback from these subjects were evaluated 
by a translation workgroup (to assess face validity) (see 
Supplementary material).
Phase III: assessment of psychometric 
properties and the validity of the final 
version of the CSI-BP
Subjects
A total of 667 chronic pain subjects and 86 healthy control 
subjects were assessed for eligibility. They were recruited 
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from local community care units, an institutional chronic pain 
clinic, by referrals from other hospital units, and by phone 
and newspaper. The recruitment process was done in conjunc-
tion with other randomized controlled trials (RCTs) run at 
the Hospital de Clínicas de Porto Alegre. These RCTs, reg-
istered at https://clinicaltrials.gov, included studies with the 
pain-related disorders FM (NCT02041455, NCT01804097), 
MPS (NCT01964729), CTTH (NCT01954277), and OA 
(NCT01747070, NCT01855958) (Figure 1). An experienced 
physician trained in chronic pain assessment and treatment 
confirmed all diagnoses in the RCTs using standardized 
evaluation criteria. For the present CSI-BP study, 222 patients 
were determined to be eligible and agreed to participate: 73 
with FM, 65 with MPS, 53 with CTTH, and 31 with OA.
Diagnoses for patients in the six RCTs were performed 
using standard assessment protocols. The diagnostic criteria 
for MPS included regional pain, normal neurologic examina-
tion, the presence of trigger points, taut bands, and tender 
points, and pain characterized as “dull”, “achy”, or “deep”. 
OA diagnoses were made according to the clinical and radio-
graphic criteria of the American College of Rheumatology. 
Also, all OA patients completed the Western Ontario and 
McMaster universities OA index, a validated measure of 
OA-related patient-reported symptoms and perceived dis-
ability.19 CTTH was diagnosed using the 2004 International 
Headache Society criteria.20 FM was diagnosed according to 
the American College of Rheumatology criteria for FM.21 In 
all six RCTs, patients were included if they had experienced 
pain scored as visual analog scale (VAS) 40 mm (ie, moderate 
or severe pain). Additionally, the pain needed to be associ-
ated with disability, as assessed by an affirmative answer to 
dichotomous questions (yes/no) of a structured questionnaire. 
Queries inquired if their pain had interfered with work, enjoy-
able activities, responsibilities at home, relationships, per-
sonal goals, thinking clearly, problem solving, concentration, 
or recall. We excluded patients with a rheumatic or neurologic 
Figure 1 Flow of the multiple standardized phases of the study.
Abbreviations: BDNF, brain-derived neurotrophic factor; CSI, Central Sensitization Inventory; CSI-BP, Central Sensitization Inventory – Brazilian population.
I. Translation
Phase I
Phase II
Phase III
Two translations (T1 & T2)
1. Professional translator
2. Linguist
Synthesize (T1; T2; T3; T4) into T-1,2,3,4
1. Professional translator
2. Linguist
3. Psychologist
4. Physician with pain specialization
Two native English speakers,
naïve outcome measures
Resolve any discrepancies with
translators’ reports
A third bilingual person highlighted
any conceptual errors or gross
inconsistencies in the
content of the translated versions
The expert committee consisted of all translators and back-translators,
one methodologist, and one clinical research scientist. The task of this
expert committee was to ensure semantic and idiomatic equivalence
and experiential and conceptual equivalence
Assessment of the meaning and understanding of each question of
the CSI in Brazilian Portuguese using a visual analogue scale
(0 [not clear] to 10 [entirely clear])
(a) 30 health professionals that work with chronic pain
(b) 20 female patients with fibromyalgia (test–retest)
Discriminate across specific conditions (fibromyalgia [n=22],
osteoarthritis [n=26], myofascial pain syndrome [n=18],
and a normative control group [n=11]; total n=77)
Assessment of convergent validity
Discriminate between those who do/do not respond to the
conditioned pain-modulation task (n=77)
Correlate the CSI-BP score with serum levels of BDNF (n=77)
(a)
(b)
(c)
Patients with chronic musculoskeletal pain (n=222) and healthy
control subjects (n=63) comprised the sample to assess the final
version of the CSI-BP (N=285)
II. Synthesis
III. Back-translation
IV. Expert committee
review
V. Pretesting
VI. Assessment of the basic psychometric
properties
VII. To assess the discriminant capability
and its correlation with biological markers
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condition, such as stroke or Parkinson’s disease, surgery 
on the affected areas in the prior 6 months, habitual use of 
corticosteroids, or other uncompensated chronic pathologies. 
We excluded patients with any malignancy diagnosis, with 
HIV, or if they were illiterate.
Healthy controls were recruited from the general popula-
tion using public postings as well. Of the 86 potential healthy 
control subjects, 63 were eligible and agreed to participate. 
A standard screening questionnaire was performed to assess 
inclusion criteria. Eligible healthy control subjects had to 
be free of any acute or chronic pain, as well as any rheuma-
tologic, psychiatric, or neurological disorders, and without 
recent use of analgesics, corticosteroids, or medications with 
known effects on the CNS. Also, healthy control volunteers 
were not included if they reported abuse of alcohol or psy-
chotropic substances in the 6 months prior to the screening. 
Unlike the patient sample, none of the control volunteers 
underwent a physical examination.
We selected 66 patients among 159 patients with chronic 
pain (OA 31, FM 77, and MPS 65) and 11 subjects among 
63 in the healthy group. The randomization procedure 
was conducted within each group of pathologies using a 
simple random method. This subsample included 26 OA, 22 
FM, 18 MPS, and 11 healthy control subjects (pain-free). 
A physician with more than 15 years of experience in a 
pain clinic and highly skilled at diagnosing chronic pain 
conditions reexamined patients and then reconfirmed their 
diagnosis. CSI-BP scores obtained in this subsample were 
used for correlations with two biological markers of CS: 
CPM task and BDNF blood sample. Also, patients answered 
questions during a structured interview, and a blood sample 
was collected.
Self-report variables
After signing informed consent, subjects completed a 
sociodemographic questionnaire that assessed variables 
including age, gender, work status due to pain, marital status, 
and education. In addition to the CSI, all subjects completed 
the Brazilian Portuguese pain-catastrophizing scale (BP-
PCS).22 This questionnaire consists of 13 items evaluating 
self-reported catastrophizing thoughts, feelings, and behav-
iors when one is in pain. Total scores, ranging from 0–52, 
are computed by summing all items on the questionnaire.22,23 
The BP-PCS evaluates aspects of pain that are related to CSI 
items, and because of this it was chosen to help the assess-
ment of CSI-BP convergent validity.
In addition to the sociodemographic questionnaire and 
BP-PCS, patients from three subsample groups (FM, OA, 
and MPS) who participated in the biological marker section of 
the study also completed two additional self-report measures. 
Pain severity was assessed by visual analogue scale (VAS). 
VAS results were converted to 0 (no pain) to 10 (worst pos-
sible). Depressive symptoms were measured with the Beck 
Depression Inventory II, adapted to Brazilian Portuguese,24 
which is an instrument recommended by the Initiative on 
Methods, Measurement, and Pain Assessment in Clinical 
Trials because of its excellent psychometric properties and 
extensive use in clinical pain research.
CS-related symptom variables
Self-reporting of previously diagnosed CSSs from the 
CSI-BP part B was evaluated. This information was used 
to provide three subject categories with presumably three 
different levels of CS involvement. The 63 healthy controls 
were allocated to the “low CS-symptom” group. Patients 
with a single diagnosis (OA, FM, MPS, or CTTH) and no 
self-reported CSS diagnosis on the CSI-BP part B com-
prised the “medium CS-symptom” group. Patients with 
multiple diagnoses (OA, FM, MPS, and CTTH) and the 
addition of one or more previous CSS diagnoses on the 
CSI-BP part B comprised the “high CS-symptom” group. 
The seven self-reported CSS diagnoses on the CSI-BP part 
B were restless-leg syndrome, chronic fatigue syndrome, 
FM, temporomandibular joint disorder, migraine or tension 
headache, irritable bowel syndrome, and multiple chemical 
sensitivities. These three subject subgroups were then evalu-
ated by total CSI scores categorized by five severity levels 
– subclinical, mild, moderate, severe, and extreme – as has 
been recommended previously.12
Assessment of serum BDNF and 
CPM task
CPM variables
The 77 subjects from the identified subsample previously 
detailed were submitted to the CPM task using the protocol 
of Tousignant-Laflamme et al,25 which allows evaluation of 
the function of the descending pain-modulatory system. By 
attempting to modify the descending pain-modulatory sys-
tem, indications of CS can be determined. Diffuse noxious 
inhibitory control was induced by immersing the nondomi-
nant hand in cold water (0°C–1°C) for 60 seconds.25,26 The 
cold-pressor test is an intense nociceptive stimulus used to 
elicit diffuse noxious inhibitory control (test stimulus) “pain 
inhibits pain”,26,27 and it allows us to modify the endog-
enous pain-modulating system. To quantify the function 
of the descending pain-modulatory system, we evaluated 
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pain intensity by quantitative sensory testing (QST).26,28 An 
experimentally predetermined test was done to determine 
individual thermal pain thresholds (TPTs), defined here as a 
numeric pain score of 6/10, using QST administered over the 
dominant forearm (the one opposite the cold-pressor test). 
In a separate test, during the last 30 seconds of cold-water 
immersion, the TPT procedure was applied to the dominant 
forearm using a temperature individually predetermined to 
induce a 6/10 pain rating during the pretesting sessions. A 
CPM score was determined by subtracting the mean pain 
scores during TPT testing: (changes on the numeric pain scale 
[0–1] during QST + cold-water minus) minus (the first TPTs 
to induce pain on the numeric pain scale [6/10] using QST). 
Negative values on the CPM score indicated that inhibitory 
CPM was achieved. If the subject did not report a reduction 
in pain or reported an increase in pain during the CPM task, 
the descending modulatory systems were considered to have 
failed to modulate the nociceptive response. For data analy-
sis, patients were divided into two groups: CPM responders, 
who reported a decrease in pain in the second TPT test, and 
CPM nonresponders, who reported no decreases or increases 
in pain during the second TPT test (indicating CPM failure 
and evidence of CS).
Serum BDNF
Because the release of BDNF has been found to be associated 
with the induction and maintenance of CS,9 blood samples 
were collected early in the morning for each subject in the 
identified subsample groups detailed previously. The blood 
samples were obtained in plastic tubes and centrifuged for 
10 minutes at 4,500 rpm at 4°C. Serum was stored at −80°C 
for further BDNF assay. Serum-mediator concentrations 
were determined using BDNF (Chemicon CYT306, lower 
detection limit 7.8 pg/mL; EMD Millipore, Billerica, MA, 
USA) enzyme-linked immunosorbent-assay kits, according 
to the manufacturer’s instructions.
Assessment of potential confounders
The physician who performed the physical evaluation 
assessed each subject’s analgesic use, which was defined as 
an average amount of analgesics used per week during the 
previous month. For data analysis, analgesic use was included 
as a dichotomous variable (the use of analgesics fewer than 
4 days per week or use more than 4 days per week). This 
approach was chosen because the use of rescue analgesics by 
patients with chronic pain often changes each week, depend-
ing on their levels of pain.
Statistical analysis
Internal consistency reliability was assessed using Cronbach’s 
a for the CSI-BP to compare with the English version. Test–
retest correlation to assess reproducibility was used, and the 
intraclass coefficient (two-way random, type absolute agree-
ment) was calculated for examining test–retest reliability.29 
For factor analysis, a principal component analysis was 
conducted using Promax rotation. To select item loading, 
0.4 was considered the relevant factor cutoff, and thus when 
the loading was less than 0.4 the item was not retained.30 
We also excluded factors with eigenvalues greater than one.
Criterion validity was evaluated using the relationship 
between total CSI-BP scores (categorized by severity level) 
and the no, low, and high CS-symptom groups. For this 
assessment, an ANOVA was followed by a Bonferroni test 
to adjust for multiple comparisons. Independent c2 tests were 
used for categorical variables, such as the presence or absence 
of the self-reported diagnosis of part B of the CSI, and the 
chronic pain syndromes with CSS-relevant factors identi-
fied by the physician. Cramer’s V was used as a measure of 
effect size for c2 tests. Convergent validity was evaluated by 
the Pearson’s correlation coefficient between CSI-BP score 
and the BP-PCS.
To determine the profile of accuracy of the CSI-BP in 
distinguishing between chronic pain subjects and pain-free 
healthy control subjects, an area under the curve (AUC) 
analysis was performed with exact binomial 95% confidence 
intervals (CIs). CSI-BP scores used to examine the AUC were 
adjusted by the effect of age, gender, years of school, and his-
tory of psychiatric diagnosis in a multiple regression model.
To assess the capability of the CSI-BP to identify the 
level of CS-related symptoms (no, low, and high) among 
the subjects with specific pain syndromes and the pain-
free healthy control subsamples (n=77), we constructed an 
adjusted index of CSI-BP, using a forward-stepwise regres-
sion to select variables to include in a hierarchical multiple 
regression.4 This model generated an adjusted score on the 
CSI-BP, which was used to assess the correlation between the 
CSI-BP and the BDNF. Student’s t-test for the independent 
sample was used to compare changes on the self-reported 
numeric pain scale (0–10) during CPM tasks, which were 
used to classify subjects into CPM responders and CMP 
nonresponders.31 To estimate sample size, we used the ratio 
of the number of subjects to the number of items.32 For all 
statistical analyses, significance was set at P<0.05. Data 
were analyzed using SPSS version 22.0 (IBM, Armonk, 
NY, USA).
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Results
Test–retest reliability of the CSI-BP
Test–retest reliability was assessed in a group of female 
patients with FM (n=20). The test–retest correlation for each 
single item was 0.84 (95% CI 0.62–0.94), and the average 
measure was 0.91 (95% CI 0.77–0.97, P<0.001 for both), 
indicating a high level of reliability between administrations. 
All item–analysis correlations were found to be statistically 
significant.
Score distributions of the CSI-BP
The demographic characteristics and scores of the CSI-BP 
parts A and B are presented in Table 1. There was a dispro-
portionate number of females (n=248) in our sample. The 
mean scores of the CSI-BP for males were 37.38 (17.05) 
and for females 46.61 (17.15) (t=–3.15, P<0.001]. The mean 
score on the CSI-BP for the total subject sample, including 
the healthy group, was 45.35 (SD 17.4). The median was 46, 
and the range was 32.5–58.
In evaluating total scores on part A of the CSI-BP, the 
FM group was statistically distinguishable from the OA and 
MPS groups, and all three chronic pain groups were statisti-
cally distinguishable from the healthy group. The mean total 
score in the FM group was nearly double that of the healthy 
control group. The average scores on FM were equivalent to 
reporting that all 25 symptoms occur “sometimes” (Table 1). 
Assessment of the number of self-reported previous CSS 
diagnoses on part B of the CSI-BP revealed that the mean 
number of diagnoses in FM was 2.21 (2.21) and MPS 2.21 
(2.08), both groups more than double that of the OA (0.64 
[0.83]). The healthy subjects averaged less than one CSS 
diagnosis (0.03 [0.17]).
Internal consistency of the CSI-BP
Cronbach’s a was 0.91, indicating that each of the items con-
tributed similarly to the construct that it intended to measure.
Confirmatory factor analysis of the  
CSI-BP
A confirmatory factor analysis was performed to investigate 
whether the original English CSI study dimensionality and 
factor-loading pattern was like the Brazilian subject sample. 
The mean (SD) of each item and the standardized factor 
loadings, including the specific CSI-BP question items, 
contributing to factors with item loading higher than 0.4 are 
shown in Table 2. The factor analysis yielded four factors 
that accounted for 49.01% of the variance in the data set.
Relationship between subject subgroups 
with different types of chronic 
musculoskeletal pain with self-reported 
levels of CS-related symptoms
Table 3 presents three subject groups determined to have 
low, medium, and high CS symptoms. Approximately 80% 
of the low CS-symptom group (ie, the nonpatient comparison 
subjects) scored below 40 and about 50% scored below 30. 
Of patients in the medium CS-symptom subgroup, defined 
as having only one of the four study diagnoses (FM, MPS, 
CTTH, and OA), 76% scored above 40. In the high CS-symp-
tom group, 57.8% scored above 50 and 29.47% scored above 
60. The CSI severity-level groupings corresponded well with 
CSI-score distributions from these different subject samples.
Relationship between scores on the  
CSI-BP and pain-catastrophizing scale
Moderate positive correlations were found between total 
scores on the CSI-BP and total scores, as well as subscale 
scores on the BP-PCS. The Pearson correlation of the CSI-BP 
with the helplessness BP-PCS subscale was r=0.68 (95% CI 
0.61–0.71), with the magnification BP-PCS subscale r=0.63 
(95% CI 0.55–0.69), with the rumination BP-PCS subscale 
r=0.62 (95% CI 0.54–0.68), and with the BP-PCS total score 
r=0.68 (95% CI 0.61–0.74).
Table 1 Demographic variables and CSI-BP scores for validation (n=285)
Variables Healthy controls1 (n=63) OA2 (n=31) MPS3 (n=65) CTTH4 (n=53) FM5 (n=73) P
Gender (female) 26 (69.8%) 31 (100%) 54 (88.5%) 29 (26.7%) 54 (94.5%) <0.001
Age (years) 38.38 (14.34) 67.03 (8.24) 43.31 (11.51) 36.23 (12.18) 49.94 (10.95) <0.001
Formal education (years) 12.14 (4.48) 15.93 (5.60) 13.93 (5.01) 12 (4.48) 15.5 (5.32) <0.001
Psychiatric disease, yes (%)§ – 9 (29%) 38 (58.46%) 17 (56.7%) 43 (58.9%) <0.001
Part B, CSI-BP (diagnoses)€ 0.68 (0.89)2–5 1.37 (1.31)1,3–5 2.83 (1.31)12 2.30 (1.02)1,2 3.23 (1.68)1,2 <0.001
CSI-BP (score)€ 37.14 (15.01)5 39.53 (16.48)5 43.13 (15.53)5 46.13 (15.83)5 58.30 (14.56)1–4 <0.001
Notes: §History of medical psychiatric disease (eg, major depression, anxiety disorder, bipolar disorder); €comparisons using ANOVA. Post hoc differences between severity-
level groups are indicated via superscript numbers.
Abbreviations: CSI-BP, Central Sensitization Inventory – Brazilian population; OA, osteoarthritis; MPS, myofascial pain syndrome; CTTH, chronic tension-type headache; 
FM, fibromyalgia.
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Ability of the CSI-BP to discriminate 
between chronic pain and pain-free 
healthy control subjects
The screening accuracy of the CSI-BP to discriminate 
between chronic pain subjects (n=222) and healthy control 
subjects (n=63) was evaluated using CSI-BP scores adjusted 
by age, gender, years of school, and history of psychiatric 
diagnosis. These variables explained 27% of the proportion of 
the variance (fluctuation) in CSI-BP scores, which showed a 
profile of accuracy using a cutoff point of 35 related to sensi-
tivity of 0.98 and specificity of 0.9, with an AUC of 0.8 (95% 
CI 0.76–0.86). These findings showed that according to this 
cutoff point, the CSI-BP classified correctly (ie, specificity) 
more than 90% of those that presented with CSS conditions.
Ability of the CSI-BP to discriminate 
between subject subsamples
The primary demographic variables and total CSI-BP scores 
for the four subsamples (healthy controls, OA, MPS, and FM) 
are presented in Table 4. There were statistically significant 
differences among the four groups on self-reported pain and 
depressive symptoms, analgesic drug use, psychiatric history, 
blood levels of serum BDNF, previous CSS diagnoses on the 
CSI part B, and total CSI-BP scores.
To obtain the purer effect of group differences, CSI-BP 
scores were adjusted using a hierarchical multiple conditional 
regression analysis, as shown in Table 5. Level of education 
was negatively correlated with the CSI-BP score, while a 
higher level of depressive symptoms, greater number of 
diagnoses on part B of the CSI-BP, and higher pain scores 
were positively correlated with the CSI-BP. Therefore, CSI-
BP scores in this model allow us to assess on a standard scale 
if the CSI-BP is an index that is related to a serum marker of 
neuroplasticity, such as serum BDNF.
Relationship between the CSI-BP and 
serum BDNF
Total CSI-BP scores were correlated with serum levels of 
BDNF, a biological marker of neuroplasticity. The scatter-
plot of the raw CSI-BP and BDNF is presented in Figure 2. 
 Pearson’s correlation coefficient was 0.52 (95% CI 0.33–0.66), 
and the coefficient of determination demonstrated that the 
proportion of variance explained by the association between 
Figure 2 Scatter plots of serum BDNF and CSI-BP (n=77).
Abbreviations: BDNF, brain-derived neurotrophic factor; CSI-BP, Central Sensitization Inventory – Brazilian population.
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the CSI-BP and the BDNF was 27% (R2=0.27). Increases in 
BDNF were associated with the higher CSI-BP scores.
Relationship between the CSI-BP and 
responses to conditioned pain-
modulation task
The difference between the CSI-BP for CPM responders and 
CPM nonresponders is shown in Figure 3. The CPM nonre-
sponders, who demonstrated dysfunction in the descending 
pain-modulatory system, had significantly higher CSI-BP 
scores than the CPM responders.
Discussion
The CSI-BP showed satisfactory psychometric evaluations, 
based on its internal consistency, construct validity, reproduc-
ibility convergent, discriminant validity, and factor structure. 
This showed that the translated version of CSI was stable 
over time, presenting excellent test–retest reliability, with a 
Table 2 Factor analysis breakdown of the CSI-BP with the specific items that contributed to each factor (n=285)
CSI-BP items Mean (SD) Physical 
symptoms
Emotional 
distress
Headache/jaw 
symptoms
Urological 
symptoms
Items not  
loading on  
factors
1. Unrefreshed in the morning 2.39 (1.18) 0.44
2. Muscles stiff/achy 2.72 (1.05) 0.88
3. Anxiety attacks 2.12 (1.13) 0.44
4. Grind clench/teeth 1.67 (1.43) 0.5
5. Diarrhea/constipation 1.79 (1.23) 0.47
6. Need help with daily activities 1.35 (1.41) 0.59
7. Sensitive to bright lights 1.75 (1.41) 0.5
8. Easily tired with physical activity 2.39 (1.28) 0.73
9. Pain all over body 1.97 (.137) 0.77
10. Headaches 1.95 (1.12) 0.6
11. Bladder/urination pain 0.69 (1.01) 0.64
12. Do not sleep well 2.17 (1.18) 0.49
13. Difficulty concentrating 2.09 (1.09) 0.78
14. Skin problems 1.74 (1.42) X
15. Stress makes symptoms worse 2.70 (1.32) 0.5
16. Sad or depressed 1.94 (1.0) 0.67
17. Low energy 2.13 (1.10) 0.46
18. Tension, neck and shoulders 2.80 (1.15) 0.63
19. Pain in jaw 0.55 (1.00) 0.48
20. Certain smells make dizzy 1.22 (1.27) 0.64
21. Urinate frequently 1.78 (1.30) 0.63
22. Restless legs 1.87 (1.49) 0.42
23. Poor memory 2.04 (1.12) 0.72
24. Trauma as child 1.21 (1.34) 0.51
25. Pelvic pain 1.26 (1.35) 0.49
Notes: The following variance was found for each factor: factor 1 (physical symptoms) 32.81%, factor 2 (headache/jaw symptoms) 5.36%, factor 3 (emotional distress) 
6.09%, and factor 4 (urological symptoms) 4.94%. The confirmatory factor analysis revealed that all items were significantly related to their specified factors, verifying the 
hypothesized relationships among the item and latent factors. It was noted that three items on the original English CSI did not load on any of the four factors, including items 
1 (unrefreshed from sleeping), 5 (problems with diarrhea and/or constipation), and 14 (skin problems). With the CSI-BP, however, item 1 was retained in factor 1 and item 
5 retained in factor 4. Item 14 did not load any of the four factors. X, excluded item in the factorial analysis.
Abbreviations: CSI, Central Sensitization Inventory; CSI-BP, Central Sensitization Inventory – Brazilian population.
Table 3 CSI-BP severity-level scores of three subject subgroups, divided into five categories of severity (n=285)
Subgroups Subclinical,  
0–29  
(n=53)
Mild,  
30–39  
(n=57)
Moderate,  
40–49  
(n=56)
Severe,  
50–59  
(n=56)
Extreme,  
50–59  
(n=62)
c2 P-value Effect  
size
Low CS-symptom group (n=63)§ 28 (52.8%) 15 (26.3%) 12 (21.4%) 4 (7%) 4 (6.5%) 38.3 0.001 0.28
Medium CS-symptom group (n=49)¥ 16 (30.2%) 10 (17.5%) 12 (21.4%) 4 (7%) 7 (11.6%) 0.31
High CS-symptom group (n=173)π 9 (17%) 32 (56.1%) 32 (57.1%) 49 (86%) 51 (82.3%) 0.16
Notes: §Healthy control group; ¥diagnosis of only one pain syndrome (OA/FM/MPS/CTTH); πtwo or more diagnosed pain syndromes, plus one or more self-reported CSS 
on CSI-BP part B. Size effect interpreted as: small, 0.10–0.29; moderate, 0.30–0.49; and large, 0.5 or higher.
Abbreviations: CSI-BP, Central Sensitization Inventory – Brazilian population; CS, central sensitization; OA, osteoarthritis; FM, fibromyalgia; MPS, myofascial pain syndrome; 
CTTH, chronic tension-type headache; CSS, central sensitivity syndrome.
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performance similar to that observed with the Dutch CSI.13 
The moderate correlation coefficient of the CSI-BP with the 
BP-PCS22 is a criterion usually considered satisfactory for 
establishing construct validity.33 Also, this finding suggests 
that catastrophizing pain has an overlap with the CS phe-
nomenon, which leads to behavioral and emotional changes 
for people experiencing chronic pain.34 This hypothesis is 
supported by a moderate positive correlation of catastroph-
izing with intracortical facilitation measured via transcranial 
magnetic stimulation in patients with chronic MPS.35
The CSI-BP showed criterion-group validity to differenti-
ate between subgroups. A cutoff of 35 found good sensitivity 
(0.98) for correctly identifying patients and good specific-
ity (0.87) for correctly identifying control subjects, which 
resulted in 80% of subjects being accurately identified. In 
addition to very good discrimination accuracy, this result 
is interesting, because a total score of 40 was previously 
determined to be the best cutoff for the English version of the 
CSI. The cutoff discrepancy between the English CSI and the 
CSI-BP is most probably explained by the different subject 
samples evaluated. Also, CSI-BP discriminatory properties 
were demonstrated to differentiate the mean among specific 
chronic pain conditions (FM, OA, CTTH, and MPS) and a 
healthy group. These results are underscored by a previous 
Table 4 Clinical and demographic characteristics among four subgroups (n=77)
Characteristics Healthy controls1 (n=11) OA2 (n=26) MPS3 (n=18) FM4 (n=22) P
Age (years)€ 40.09 (10.93)2,4 67.5 (8.08)2–4 48.66 (10.14)2,4 53.72 (6.97)1,2 0.001
Formal education (years)€ 18.36 (2.06)2–4 8.84 (3.27)1,3 14.16 (6.0)1,2,4 9.46 (4.19)1,3 0.001
Number of chronic diseases NA 14 (53.84%) 8 (44.44%) 15 (68.18%) 0.21
Analgesic drugs used, yes£ NA 10 (38.46%) 14 (77.77%) 20 (90.9%) <0.001
Working, yes 0 4 (15.4%) 3 (16.7%) 6 (26.3%) 0.13
History of psychiatric disease, yes NA 7 (26.9%) 9 (50%) 12 (54.5%) <0.001
BDNF (ng/mL)€ 16.1 (5.74)2–4 24.95 (20.30)1,3 29.44 (19.76)1,4 53.13 (27.94)1–3 <0.001
CPM responders (normal response) 11 (100%) 17 (64.5%) 13 (72.2%) 8 (36.4%) 0.04
Pain on VAS€ 1.89 (1.24)2–4 6.61 (1.89)1 6.90 (2.67)1 6.80 (1.70)1 <0.001
Pain-pressure threshold€ NA 3.88 (1.57)4 4.46 (3.64)4 2.10 (1.28)2,3 <0.001
Beck Depression Inventory II€ 3.28 (2.09)2–4 11.61 (8.13)1,3,4 17.67 (10.94)1,2 17.00 (6.11)1,2 <0.001
Number of diagnoses, part B CSI-BP€ 0.63 (0.92)2–4 1.34 (1.23)1,3,4 2.40 (1.75)1,2 2.95 (1.49)1,2 <0.001
CSI-BP€ 31.18 (11.57)2–4 40.61 (10.38)1,4 41.22 (10.38)1,4 57.54 (12.38)1–3 <0.001
Notes: Data presented as n (%) or mean (SD). €Comparisons using ANOVA. Post hoc differences of 0.05 among groups indicated via superscript numbers. £Analgesic drugs 
used more than three times per week during the last 3 months. CPM responders who reported a decrease in pain in the second TPT test, and CPM nonresponders, who 
reported no decreases, or increases in pain, during the second TPT test (indicating CPM failure and evidence of CS).
Abbreviations: OA, osteoarthritis; MPS, myofascial pain syndrome; FM, fibromyalgia; NA, not applicable; BDNF, brain-derived neurotrophic factor; CPM, conditioned pain 
modulation; VAS, visual analogue scale; CSI-BP, Central Sensitization Inventory – Brazilian population; TPT, thermal pain threshold; CS, central sensitization.
Table 5 Hierarchical multiple conditional regression analysis to adjust CSI-BP score for potential confounders (n=77)
V SE b t P
Years at school* –1.087 0.395 –0.303 –2.75 0.007
Beck Depression Inventory§ 1.105 0.196 0.546 5.64 0.000
Number of diagnoses, part B CSI-BP# 3.548 1.155 0.301 3.07 0.003
Visual analogue scale$ 1.519 0.696 0.228 2.18 0.032
Notes: *Model 1, age, gender, and formal education; §model 2, model 1 depressive symptoms and use of psychotropic medications; #model 3, model 2 plus analgesics used 
at least three times/week in last 3 months and pain scores on the visual analogue scale and number of diagnoses of part B of CSI-BP; $model 4, model 3 plus type of chronic 
pain syndrome that could have been affected by all the variables studied in the previous hierarchical levels.
Abbreviations: CSI-BP, Central Sensitization Inventory – Brazilian population; SE, standard error.
Figure 3 Comparisons of the CSI-BP between nonresponders (NPS0–10 HPT1 – 
HPT0 ≥0, n=28) and responders (NPS0–10 HPT1 – HPT0 <0, n=49) (total (n=77).
Notes: *Differences between groups (responders and nonresponders to 
conditioned pain-modulation task) compared by t-test for independent samples. 
Error bars indicate standard deviation of the mean.
Abbreviations: CSI-BP, Central Sensitization Inventory – Brazilian population; 
HPT, heat pain threshold; NPS, numeric pain scale.
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study in chronic pain and specialized clinic pain.36 Selection 
bias was possible, and as such the external validity of these 
results to other samples of chronic pain patients from dif-
ferent settings is uncertain, such as patients under the care 
of a family physician. Although our data are consistent with 
findings observed in the original version and adapted and 
published into various European, Asian, and South American 
languages,14–18 future research could evaluate the utility of 
the instrument in heterogeneous-sample subjects in diverse 
clinical settings.
Validity was also assessed with two objective biological 
markers of CS. The results of the CPM task categorized 
subjects into two groups. Subjects who showed that inhibi-
tory CPM was achieved were classified as CPM responders. 
Subjects who showed a failure of the descending modulatory 
system to modulate the nociceptive response (indicating 
CS) were categorized as CPM nonresponders. According 
to a spectrum of responders and nonresponders to the CPM 
task, the current findings suggest a relationship between the 
descending modulatory system and subjects with presumably 
different levels of CS-related symptomatology, from patients 
with FM to healthy control subjects. The CPM task evaluated 
self-reported pain levels, but CS is not only associated with 
pain. It can also affect cognitive and emotional functioning 
in general.37 This statement is supported by similar dysfunc-
tion in the descending pain-modulatory system reported 
in lesions in brain regions implicated in descending pain 
modulation (ie, traumatic brain injury and multiple sclerosis), 
including the medial prefrontal cortex and rostral anterior 
cingulate cortex.38 Additionally, this dysfunction has been 
demonstrated when alterations occurred in the integrity of 
brain regions involved in both pain control and cognitive 
and emotional functioning. Thereby, changes in this network 
could explain the relationship between the severity of the 
self-reported CS-related symptoms on the CSI-BP and the 
dysfunction of the corticospinal pain-modulatory system 
measured by the CPM task. As is known, the activity of 
interneurons in the descending inhibitory system is mediated 
by the synthesis of neurotransmitters (GABA and glycine), 
serotonin, and norepinephrine.39 However, a lack of function 
in the descending pain-modulatory system as assessed by 
the CPM task suggests that the role of these neurobiological 
systems is weak, and a greater score on the CSI-BP in CPM 
nonresponders indicates higher dysfunction in the inhibitory 
descending network.
This is an interesting finding with potential applicability 
to help clinicians personalize the best therapeutic approach 
based on the level of CS-related symptomatology of each 
patient. Particularly intriguing is how CPM serves as a 
marker with a large size effect to identify impairment of the 
descending pain-modulatory system in populations with 
long-term pain conditions.40 In another way, this finding 
assesses a consequent downward negative spiral of pain 
induced by chronic pain. While these results need to be 
confirmed in further studies before allowing for a definitive 
conclusion, according to recent research in our laboratory, 
we demonstrated that the loss of descending pain inhibition 
was associated with an increase in intracortical facilitation 
measured by transcranial magnetic stimulation, higher 
serum BDNF, and a greater level of disability related to 
pain.41 Therefore, the relationship between the variation in 
CSI-BP and CPM scores could represent the imbalance in 
the neuroplasticity mediators involved in the modulation of 
the excitatory/inhibitory CNS. Therefore, a higher score on 
the CSI may be useful in helping to identify patients prone 
to severe chronic pain or those with a greater propensity 
to respond to certain treatments, such as demonstrated by 
duloxetine in treating neuropathic pain and OA.42,43 Future 
studies should investigate if CSI scores can be a useful tool 
for evaluating new approaches for improving the function of 
the neurobiological systems involved in CS and CSS.
The CSI-BP in the present study was also correlated with 
serum BDNF. There is compelling evidence that BDNF is a 
ubiquitous pain mediator at many levels of the nervous sys-
tem and that serum levels are an indirect assessment of the 
neuroplasticity changes associated with CS. Accordingly, it 
has also been demonstrated that vascular circulating BDNF 
represents 70%–80% of that produced in the CNS.44 Although 
the transport of BDNF produced in the CNS occurs through 
the blood–brain barrier via saturable systems, it has been 
widely demonstrated using different approaches with effect in 
the CNS that variations in the serum levels of this neurotrophic 
factor reflect the impact of such interventions. Included among 
such interventions are antidepressant drugs, electroconvulsive 
therapy,45 electroacupuncture,6 transcranial magnetic stimula-
tion,46 and transcranial direct current stimulation.47 Therefore, 
this set of evidence shows that changes in peripheral BDNF 
levels are associated with changes involving a neuroplasticity 
process. As such, the moderate positive correlation between 
BDNF and the CSI-BP suggests that chronic pain can induce 
reorganization of the circuits involved in pain processing, 
which can at least in part be measured by changes in CSI-BP 
scores. Nevertheless, we should exercise parsimony in the 
interpretation of these results, because we can only indirectly 
infer if changes in BDNF are related to the severity of CS 
symptoms assessed by the CSI-BP.
Journal of Pain Research  2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2119
CSI-BP and its relationship with biological markers
The present study shows that the CSI-BP is related to 
markers that comprise the neuroplasticity processes involved 
in CS-related symptoms (ie, BDNF). However, several 
potential limitations in this study need to be addressed. First, 
considering there was a nonrandom selection of patients, we 
cannot exclude some selection bias, although we had recruited 
subjects in a pain clinic from the primary units and by news-
paper publicity. However, it is noteworthy that our results 
are supported by psychophysical and biomarkers less prone 
to possible bias. Second, our study presents an imbalance in 
the number of male to female subjects, which may influence 
gender differences in attitudes and health behavior.48 Also, we 
observed an imbalance in several characteristics between pain 
syndromes, which can affect CSI-BP score, biological BDNF 
secretion, and the function of the descending pain-modulatory 
system.32 Third, in a clinical study it is not possible to directly 
assess and isolate the effect of each of these potential con-
founding factors in BDNF secretion or in the descending pain-
modulatory system by CSI measures. Therefore, to generate a 
CSI-BP adjusted by the imbalance between the covariates, we 
constructed an adjusted index using a hierarchical regression 
model based on propensity-score calibration.49 The CSI-BP 
controlled for the potential concealed influence of these set 
of factors, allowing us to evaluate the relationship between 
CSI-BP score as the dependent variable and the BDNF and in 
the descending pain-modulatory system function on a standard 
scale.46,50 Fourth, years of schooling showed a negative cor-
relation with CSI-BP score. It is plausible that low literacy 
is associated with a variety of adverse health conditions and 
presents a barrier to effective care. The positive correlation 
between depressive symptoms and the CSI-BP may concern 
the cognitive, psychological, and behavioral changes observed 
in patients with chronic pain,51 since the depression itself is 
related to worse health status. Finally, the recommended CSI 
symptom-severity levels can provide a guideline for interpret-
ing CSI scores in research trials and clinical decision making.13
This study provides evidence for the consistent psycho-
metric properties of the CSI-BP. The CSI-BP showed good 
discriminative properties and associations with biological 
markers of CS, including serum BDNF and dysfunction of 
the descending pain-modulatory system. Therefore, these 
results suggest that the CSI-BP represents a valuable tool for 
use in scientific studies and in the clinical setting involving 
patients with chronic pain.
Acknowledgments
This research was supported by grants and material support 
from the following Brazilian agencies: Committee for the 
Development of Higher Education Personnel (CAPES - 
PNPD/CAPES) (grants to LCA) and material support; 
National Council for Scientific and Technological Develop-
ment (CNPq) (grants to ILST and WC); Postgraduate Pro-
gram in Medical Sciences at the School of Medicine of the 
Federal University of Rio Grande do Sul (material support); 
Postgraduate Research Group at the Hospital de Clínicas 
de Porto Alegre (FIPE-HCPA) (material support); and the 
Brazilian Innovation Agency (FINEP) (process number 
1245/13; WC).
Author contributions
All authors made a significant contribution to study concept 
and design, acquisition of data, or analysis and interpretation 
of data, drafting or revising the manuscript for important 
intellectual content, and approval of the final version to be 
published.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence 
of chronic pain in the UK: a systematic review and meta-analysis of 
population studies. BMJ Open. 2016;6(6):e010364.
 2. Miranda VS, Decarvalho VB, Machado LA, Dias JM. Prevalence of 
chronic musculoskeletal disorders in elderly Brazilians: a systematic 
review of the literature. BMC Musculoskelet Disord. 2012;13:82.
 3. Schur EA, Afari N, Furberg H, et al. Feeling bad in more ways than 
one: comorbidity patterns of medically unexplained and psychiatric 
conditions. J Gen Intern Med. 2007;22(6):818–821.
 4. Deitos A, Dussán-Sarria J, Souza A, et al. Clinical value of serum neu-
roplasticity mediators in identifying the central sensitivity syndrome in 
patients with chronic pain with and without structural pathology. Clin 
J Pain. 2015;31(11):959–967.
 5. Yunus MB. Central sensitivity syndromes: a unified concept for 
fibromyalgia and other similar maladies. J Indian Rheum Assoc. 
2000;8(1):27–33.
 6. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: 
Do pain and memory share similar mechanisms? Trends Neurosci. 
2003;26(12):696–705.
 7. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. 
Science. 2000;288(5472):1765–1769.
 8. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain 
hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926.
 9. Trang T, Beggs S, Salter MW. Brain-derived neurotrophic factor from 
microglia: a molecular substrate for neuropathic pain. Neuron Glia Biol. 
2011;7(1):99–108.
10. Nijs J, Torres-Cueco R, van Wilgen CP, et al. Applying modern pain 
neuroscience in clinical practice: criteria for the classification of central 
sensitization pain. Pain Physician. 2014;17(5):447–457.
11. Nijs J, Apeldoorn A, Hallegraeff H, et al. Low back pain: guidelines 
for the clinical classification of predominant neuropathic, nocicep-
tive, or central sensitization pain. Pain Physician. 2015;18(3): 
E333–E346.
12. Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing 
clinically relevant severity levels for the central sensitization inventory. 
Pain Pract. 2017;17(2):166–175.
Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2120
Caumo et al
13. Kregel J, Vuijk PJ, Descheemaeker F, et al. The Dutch central sensi-
tization inventory (CSI): factor analysis, discriminative power, and 
test-retest reliability. Clin J Pain. 2015;32(7):624–630.
14. Bid D, Neela S, Rathod PV, Ramalingam T. Content validity and test-
retest reliability of the Gujarati version of the central sensitization 
inventory. Natl J Integr Res Med. 2016;7(5):18–24.
15. Cuesta-Vargas AI, Roldan-Jimenez C, Neblett R, Gatchel RJ. Cross-
cultural adaptation and validity of the Spanish central sensitization 
inventory. SpringerPlus. 2016;5(1):1837.
16. Knezevic A, Neblett R, Jeremic-Knezevic M, Tomasevic-Todorovic S, 
Boskovic K, Cuesta-Vargas AI. Cross cultural adaptation and psycho-
metric validation of the Serbian version of the Central Sensitization 
Inventory (CSI). Pain Pract. Epub August 4, 2017.
17. Kregel J, Vuijk PJ, Descheemaeker F, et al. The Dutch central sensi-
tization inventory (CSI): factor analysis, discriminative power, and 
test-retest reliability. Clin J Pain. 2016;32(7):624–630.
18. Pitance L, Piraux E, Lannoy B, et al. Cross cultural adaptation, reliability 
and validity of the French version of the central sensitization inventory. 
Man Ther. 2016;25:e83–e84.
19. Jinks C, Jordan K, Croft P. Measuring the population impact of knee 
pain and disability with the Western Ontario and McMaster universities 
osteoarthritis index (WOMAC). Pain. 2002;100(1–2):55–64.
20. Olesen J. The International Classification of Headache Disorders: 2nd 
edition (ICHD-ll). Rev Neurol (Paris). 2005;161(6–7):689–691.
21. Wolfe F, Häuser W. Fibromyalgia diagnosis and diagnostic criteria. Ann 
Med. 2011;43(7):495–502. 
22. Sehn F, Chachamovich E, Vidor LP, et al. Cross-cultural adaptation and 
validation of the Brazilian Portuguese version of the pain catastrophizing 
scale. Pain Med. 2012;13(11):1425–1435.
23. Sullivan MJ, Bishop SR, Pivik J. The pain catastrophizing scale: devel-
opment and validation. Psychol Assess. 1995;7(4):524–532.
 24. Gomes-Oliveira MH, Gorenstein C, Neto FL, Andrade LH, Wang YP. Vali-
dation of the Brazilian Portuguese version of the Beck Depression Inven-
tory-II in a community sample. Rev Bras Psiquiatr. 2012;34(4):389–394.
25. Tousignant-Laflamme Y, Pagé S, Goffaux P, Marchand S. An experi-
mental model to measure excitatory and inhibitory pain mechanisms 
in humans. Brain Res. 2008;1230:73–79.
26. von Baeyer CL, Piira T, Chambers CT, Trapanotto M, Zeltzer LK. 
Guidelines for the cold pressor task as an experimental pain stimulus 
for use with children. J Pain. 2005;6(4):218–227.
27. Willer JC, De Broucker T, Le Bars D. Encoding of nociceptive thermal 
stimuli by diffuse noxious inhibitory controls in humans. J Neuro-
physiol. 1989;62(5):1028–1038.
28. Schestatsky P, Stefani LC, Sanches PR, et al. Validation of a Brazilian 
quantitative sensory testing (QST) device for the diagnosis of small 
fiber neuropathies. Arq Neuropsiquiatr. 2011;69(6):943–948.
29. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater 
reliability. Psychol Bull. 1979;86(2):420–428.
30. Fayers PM, Machin D. Quality of Life: Assessment, Analysis and Inter-
pretation. Chichester, UK: John Wiley & Sons; 2000.
31. Botelho L, Morales-Quezada L, Rozisky J, et al. A framework for 
understanding the relationship between descending pain modulation, 
motor corticospinal, and neuroplasticity regulation systems in chronic 
myofascial pain. Front Hum Neurosci. 2016;10:308.
32. Rouquette A, Falissard B. Sample size requirements for the internal valida-
tion of psychiatric scales. Int J Methods Psychiatr Res. 2011;20(4):235–249.
33. Peterson RA. A meta-analysis of Cronbach’s coefficient α. J Consum 
Res. 1994;21(2):381–391.
34. Trivedi MH. The link between depression and physical symptoms. Prim 
Care Companion J Clin Psychiatry. 2004;6 Suppl 1:12–16.
35. Lumly MA, Cohen JL, Borszcz GS, et al. Pain and emotion: a bio-
psychosocial review of recent research. J Clin Psychol. 2011;67(9): 
942–968.
36. Mayer TG, Neblett R, Cohen H, et al. The development and psycho-
metric validation of the central sensitization inventory. Pain Pract. 
2012;12(4):276–285.
37. Bushnell MC, Ceko M, Low LA. Cognitive and emotional con-
trol of pain and its disruption in chronic pain. Nat Rev Neurosci. 
2013;14(7):502–511.
38. Pessoa L. On the relationship between emotion and cognition. Nat Rev 
Neurosci. 2008;9(2):148–158.
39. Lewis GN, Heales L, Rice DA, Rome K, McNair PJ. Reliability of the 
conditioned pain modulation paradigm to assess endogenous inhibitory 
pain pathways. Pain Res Manag. 2012;17(2):98–102.
40. Caumo W, Deitos A, Carvalho S, et al. Motor cortex excitability and 
BDNF levels in chronic musculoskeletal pain according to structural 
pathology. Front Hum Neurosci. 2016;10:357.
41. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky 
Y. Conditioned pain modulation predicts duloxetine efficacy in painful 
diabetic neuropathy. Pain. 2012;153(6):1193–1198.
42. Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on 
osteoarthritis knee pain: a meta-analysis of randomized controlled trials. 
Pain Med. 2015;16(7):1373–1385.
43. Rasmussen P, Brassard P, Adser H, et al. Evidence for a release of 
brain-derived neurotrophic factor from the brain during exercise. Exp 
Physiol. 2009;94(10):1062–1069.
44. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis 
of clinical studies on major depression and BDNF levels: implications 
for the role of neuroplasticity in depression. Int J Neuropsychophar-
macol. 2008;11(8):1169–1180.
45. Brunoni AR, Baeken C, Machado-Vieira R, Gattaz WF, Vanderhasselt 
MA. BDNF blood levels after electroconvulsive therapy in patients with 
mood disorders: a systematic review and meta-analysis. World J Biol 
Psychiatry. 2014;15(5):411–418.
46. Dall’Agnol L, Medeiros LF, Torres IL, et al. Repetitive transcranial 
magnetic stimulation increases the corticospinal inhibition and the 
brain-derived neurotrophic factor in chronic myofascial pain syndrome: 
an explanatory double-blinded, randomized, sham-controlled trial. 
J Pain. 2014;15(8):845–855.
47. Brietzke A, Rozisky J, Dussan-Sarria J, et al. Neuroplastic effects of 
transcranial direct current stimulation on painful symptoms reduction in 
chronic hepatitis C: a phase II randomized, double blind, sham controlled 
trial. Front Neurosci. 2016;9:498.
48. Ray-Mazumder S. Role of gender, insurance status and culture in 
attitudes and health behavior in a US Chinese student population. Ethn 
Health. 2001;6(3–4):197–209.
49. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores 
and review of their use in pharmacoepidemiology. Basic Clin Pharmacol 
Toxicol. 2006;98(3):253–259.
50. Stefani LC, Torres IL, de Souza IC, Rozisky JR, Fregni F, Caumo W. 
BDNF as an effect modifier for gender effects on pain thresholds in 
healthy subjects. Neurosci Lett. 2012;514(1):62–66.
51. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation 
for chronic widespread pain in patients with fibromyalgia and chronic 
fatigue syndrome. Clin Rheumatol. 2007;26(4):465–473.
Journal of Pain Research  2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2121
CSI-BP and its relationship with biological markers
Supplementary material
Phase I: translation, synthesis, and back-
translation
Translation
The original English version of the Central Sensitization 
Inventory (CSI) was translated into Brazilian Portuguese. 
Cross-cultural adaptation was carried out by previously 
published guidelines.1–3 Four native Brazilian Portuguese 
speakers carried out independent translations of the pain-
catastrophizing scale from English to Brazilian Portuguese: 
a professional translator, a psychologist, a physician with 
pain specialization, and a linguist. Forward-translations were 
compared with one another and with the original English 
version. After discussing any discrepancies, the four versions 
were combined into one Brazilian Portuguese version.
Several items were difficult to translate between English 
and Brazilian Portuguese. For item 3 (anxiety attacks), we 
decided to use the term “crises”. For item 11, “discomfort in 
the bladder” was modified to “discomfort and burning sen-
sation”. For item 25, “trauma” was amended to “suffering”, 
because “trauma” in Brazilian Portuguese is more associated 
with physical lesions.
Back-translation
Two native English speakers translated the original CSI to 
Brazilian Portuguese and also carried out a back-translation 
into English. Brazilian Portuguese was their second language. 
According to the definition of Deyo,4 both back-translators 
were considered bilingual, but they were not familiar with 
the subject matter of the questionnaire. Any gross inconsis-
tencies or conceptual errors in the content of the translated 
versions in preparation for the expert committee meeting 
were corrected by a third bilingual person.
Delphi method to assess semantics and conceptual 
content of each item
A team of experts assessed each translated CSI item to 
ensure content validity. The expert committee consisted 
of one methodologist, one clinical research scientist, and 
all of the translators and back-translators. This expert 
panel was responsible for ensuring semantic and idiomatic 
equivalence and experiential and conceptual equivalence 
(ie, to address any peculiarities unique to the cultures 
examined) between the Brazilian Portuguese and English 
versions of the questionnaire. The committee members 
and the panel director corresponded by electronic com-
munication. The panel director processed CSI adapted for 
a Brazilian population (CSI-BP) item information from the 
committee members and filtered out the relevant content 
until everyone came to a consensus on the content of each 
item on the CSI. If a consensus could not be reached on 
specific items, rounds coordinated by two clinical research 
scientists with experience in validating instruments were 
made until they came to a final consensus.5 All changes on 
the CSI-BP items were based on the consensus of mem-
bers involved in the translation process. Their goal was 
to assure that each CSI item on the English and Brazilian 
versions referred to the same underlying concepts and 
had the same meanings, to produce the best idiomatic and 
conceptual (rather than merely literal) equivalence. The 
forward-translations were compared with one another and 
with the original English version. The forward-translations 
were compared with the original English version. As a 
result of this process, a pilot version of the CSI-BP was 
completed.
Phase II: pretesting of CSI-BP
Assessment of CSI-BP in the pilot version
Thirty medical school employees – half men, half women – 
who work with chronic pain patients volunteered to evaluate 
the meaning of the translated questions and the layout of 
the “prefinal” version of the CSI-BP. In addition, they were 
interviewed to explore how they understood each of the 25 
items. They had an average age of 30.67 (8.89 SD) years 
and an average of 19.56 formal years of schooling. Each 
employee’s self-reported comprehension of the items was 
assessed with a 10 cm visual analogue scale (VAS; from 0 
representing unclear to 10 representing entirely clear). The 
global mean ± SD of comprehension of the 25 questions of 
CSI was 9.42±1.23.
In addition to the medical school employees, 20 females 
with fibromyalgia volunteered to evaluate the meaning of 
the translated CSI-BP questions using the same VAS and 
interview process as the medical school employees. Their 
mean ± SD for number of years of formal schooling was 
10.41±4.35, and their mean age was 50.77±9.88 years. The 
global mean ± SD of comprehension of the 25 questions of 
CSI-BP reported on the VAS was 8.01±1.21.
All feedback from these subjects was evaluated by the 
translation workgroup (to assess face validity). Based on 
subject feedback, two questions were slightly modified to 
achieve the final Brazilian Portuguese version of the CSI-
BP. The final version of the CSI-BP is presented at http://
dorneuromodulacao.com.br.
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